Outcomes of patients with stage I–II Hodgkin lymphoma who had uniform pre-treatment staging with PET/CT and treatment with limited field radiation therapy after chemotherapy-Reference-Cited by-同舟云学术

Outcomes of patients with stage I–II Hodgkin lymphoma who had uniform pre-treatment staging with PET/CT and treatment with limited field radiation therapy after chemotherapy

Published:2022-08-22 Issue:8 Volume:12 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Frechette Kelsey M.,Lester Scott C.,Taparra Kekoa^ORCID,Breen William G.,Martenson James A.,Hoppe Bradford S.,Peterson Jennifer L.,Rule William G.,Stafford Scott L.,Stish Bradley J.,Habermann Thomas M.,Young Jason R.^ORCID,Harmsen William S.,Laack Nadia N.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

https://www.nature.com/articles/s41408-022-00711-8.pdf

Reference15 articles.

1. Sasse S, Brocklemann PJ, Goergen H, Plutschow A, Muller H, Kreissl S, et al. Long-term follow-up of contemporary treatment in early-stage Hodgin lymphoma: updated analysis of the German Hodgkin Study Group HD7, dh8, HD10 and HD 11 trials. J Clin Oncol. 2017;18:1999–2007.

2. Campbell B, Voss N, Pickles T, Morris J, Gascoyne R, Savage K, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin’s lymphoma: a question of field size. J Clin Oncol. 2008;32:5170–4.

3. Campbell BA, Hornby C, Cunninghame J, Burns M, MacManus M, Ryan G, et al. Minimising critical organ irradiation in limited stage Hodgkin lymphoma: A dosimetric study of involved node radiotherapy. Ann Oncol. 2012;23:1259–66.

4. Verhappen MH, Poortmans PMP, Raaijmakers E, Raemaekers JMM. Reduction of the treated volume to involved node radiation therapy as part of combined modality treatment for early stage aggressive non-Hodgkin lymphoma. Radiother Oncol. 2013;109:133–9.

5. Specht L, Yahalom J, Illidge T, Berthelsen AK, Constine LS, Eich HT, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89:854–862.